Group 1: Macro Trends - Shenzhen Stock Exchange will launch the Shenzhen Specialized and Innovative Index and the ChiNext Specialized and Innovative Index on July 21, 2025, to support the development of "little giant" enterprises [1] - Shanghai Stock Exchange will also release the Shanghai Sci-Tech Innovation Board Specialized and Innovative Index and the Shanghai Specialized and Innovative Index on July 21, 2025, providing diverse performance benchmarks and investment targets [2] Group 2: Industry Developments - Four departments, including the National Development and Reform Commission, issued a notice to promote the scientific planning and construction of high-power charging facilities, focusing on public transport, logistics, and heavy-duty freight [3] - As of June 2025, China's foreign exchange reserves reached $33,174 billion, an increase of $32.2 billion from May, reflecting a 0.98% rise due to macroeconomic policies and asset price changes [4] - In the first five months of 2025, China's textile industry saw a 3.4% year-on-year increase in industrial added value, with significant growth in production and exports [5] Group 3: Regulatory Changes - A new mandatory national standard for passenger car braking systems will be implemented on January 1, 2026, introducing requirements for electric transmission braking systems and single-pedal braking [6][7] Group 4: Company News - Xinyada announced that its cross-border payment business will account for less than 5% of total revenue in 2024, indicating limited impact on overall operations [8] - Landa Technology is planning a change in control, with stock suspension effective July 8, 2025, due to potential share transfer by major shareholders [9] - ST Texin will suspend trading for one day on July 8, 2025, and will remove other risk warnings, changing its stock name from "ST Texin" to "Tefa Information" [10] - Shanghai Washba intends to participate in the public auction for the transfer of lithium sulfide business assets from Yuyuan Rare Earth, with the outcome uncertain [11] - Tuoxin Pharmaceutical received approval for the market launch of its raw material drug, cytidine diphosphate choline, from the National Medical Products Administration [12]

Core Viewpoint - The approval of the raw material drug cytidine diphosphate choline by the National Medical Products Administration marks a significant milestone for the company, enhancing its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Xinxiang Pharmaceutical, received the "Approval Notification for Chemical Raw Material Drug Listing Application" for cytidine diphosphate choline [1] - This approval indicates that the product meets national drug review technical standards and has passed GMP compliance checks [1] Group 2: Product Significance - Cytidine diphosphate choline is commonly used as a neuroprotective agent and brain metabolism activator, with its core pharmacological action being the improvement of brain function and promotion of nerve repair [1] - The clinical application range includes patients with brain injuries, cerebrovascular diseases, and neurodegenerative diseases [1] Group 3: Market Impact - The approval will effectively broaden the company's product line and enhance its market competitiveness in the active pharmaceutical ingredient sector [1]